221 related articles for article (PubMed ID: 21258806)
1. Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.
Seidel C; Fenner M; Merseburger AS; Reuter C; Ivanyi P; Länger F; Ganser A; Grünwald V
World J Urol; 2011 Jun; 29(3):355-60. PubMed ID: 21258806
[TBL] [Abstract][Full Text] [Related]
2. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.
Grünwald V; Weikert S; Seidel C; Busch J; Johannsen A; Fenner M; Reuter C; Ganser A; Johannsen M
Onkologie; 2011; 34(6):310-4. PubMed ID: 21625184
[TBL] [Abstract][Full Text] [Related]
4. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
5. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Albiges L; Oudard S; Negrier S; Caty A; Gravis G; Joly F; Duclos B; Geoffrois L; Rolland F; Guillot A; Laguerre B; Legouffe E; Kohser F; Dietrich PY; Theodore CA; Escudier B
J Clin Oncol; 2012 Feb; 30(5):482-7. PubMed ID: 22231040
[TBL] [Abstract][Full Text] [Related]
6. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.
Bex A; van der Veldt AA; Blank C; van den Eertwegh AJ; Boven E; Horenblas S; Haanen J
World J Urol; 2009 Aug; 27(4):533-9. PubMed ID: 19145434
[TBL] [Abstract][Full Text] [Related]
11. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
14. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
[TBL] [Abstract][Full Text] [Related]
15. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
[TBL] [Abstract][Full Text] [Related]
16. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
[TBL] [Abstract][Full Text] [Related]
18. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
19. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
20. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
